What documentation is required for each sale of low-dose codeine products?

The correct choice highlights the necessity for proper documentation of low-dose codeine products in the pharmacy's patient profile and the Pharmacy Information Program (PIP). This requirement is in place to ensure that there is a comprehensive record of all transactions involving these products, which allows for monitoring and oversight pertaining to patient safety, the potential for misuse, and the legal distribution of controlled substances.

Maintaining documentation in a patient's profile ensures that pharmacists have access to critical information about a patient's medication history and therapeutic needs during subsequent visits. This helps flag any potential interactions or conflicts and contributes to the overall continuity of care.

Furthermore, recording this information in the PIP is essential for regulatory compliance, as it allows for centralized data collection and monitoring. The PIP serves as a valuable tool for the province to track prescription patterns and identify trends that may indicate misuse or diversion of controlled substances.

Overall, the requirement for such documentation is rooted in public health and safety considerations, aiming to protect patients and ensure responsible pharmacy practices.